Interim Data Shows Romiplostim May Lead to Positive Long-Term Response in Pediatric ITP

Share this content:
In these studies, children with ITP who had received romiplostim 1 to 10 μg/kg subcutaneously for 3 years or less were evaluated.
In these studies, children with ITP who had received romiplostim 1 to 10 μg/kg subcutaneously for 3 years or less were evaluated.

Subcutaneous romiplostim leads to favorable long-term platelet response rates among children with immune thrombocytopenic purpura (ITP), according to a poster presentation at the 23rd Congress of the European Hematology Association (EHA).

For these phase 1/2 and 3 studies, 203 children with ITP who had received romiplostim 1 to 10 μg/kg subcutaneously for 3 years or less were evaluated. Eligible patients had a median age of 10 years, received ITP diagnosis at least 6 months prior, were previously treated for ITP, and had screening platelet counts of 30×109/L or lower or uncontrolled bleeding. Bone marrow biopsies were evaluated at baseline and at 1 or 2 years, and/or at the end of treatment.

Interim data showed that after a median treatment duration of 53 weeks, the median percentage of time with a platelet response — defined as a platelet count of at least 50×109/L and no use of any rescue medications in the past 4 weeks — in the first 6 months was 50%. The platelet response rate was 88% over the course of the study, and median platelet counts exceeded 50×109/L starting from week 12.

The median average weekly dose throughout the study was 6.9 μg/kg, with median weekly doses of 9.0 μg/kg and 10.0 μg/kg at 1 and 2 years, respectively.

Overall, 64 patients discontinued therapy; the most common causes were lack of efficacy (38), patient request (7), and adverse events (AEs; 7).

Forty-one (20%) patients had serious AEs, including epistaxis (5% of patients) and decreased platelet counts (3% of patients). Other treatment-related AEs included headaches, abdominal pain, presyncope, and neutralizing antibodies. Grade 3 or worse bleeding was observed in 8% of patients, and 2 patients had grade 4 bleeding events.

Reference

Grainger J, Bussel J, Tarantino M, et al. A single-arm, open-label, long-term efficacy and safety study of subcutaneous (SC) romiplostim in children with immune thrombocytopenia (ITP). Poster presentation at: 23rd Congress of EHA; June 14-17, 2018; Stockholm, Sweden.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs